Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy

Sleep Medicine

Volumn 15, Issue 6, 2014, Pages 614-618

  Heier, M S ^a   Skinningsrud, A ^b   Paus, E ^a   Gautvik, K M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Amyloid; Cataplexy; Enolase; Hypocretin; Narcolepsy; Tau proteins

Indexed keywords

AMYLOID BETA PROTEIN; NEURON SPECIFIC ENOLASE; OREXIN A; TAU PROTEIN; BIOLOGICAL MARKER; ENOLASE; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CATAPLEXY; CELL METABOLISM; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NARCOLEPSY; NERVE CELL NETWORK; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SLEEP WAKING CYCLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; YOUNG ADULT;

ADULT; AGED; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NARCOLEPSY; NEUROPEPTIDES; PHOSPHOPYRUVATE HYDRATASE; TAU PROTEINS; YOUNG ADULT;

EID: 84901602241     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2014.02.005     Document Type: Article

References (50)

1. American Academy of Sleep Medicine The international classification of sleep disorders 2005, American Academy of Sleep Medicine, Westchester, IL. 2nd. ed. Diagnostic and coding manual.
2. Gautvik K.M., de Lecea L., Gautvik V.T., Danielson P.E., Tranque P., Dopazo A., et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional PCR subtraction. Proc Natl Acad Sci USA 1996, 93:8733-8738.
3. De Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998, 95:322-327.
4. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:467-474.
5. Heier M.S., Evsiukova T., Vilming S., Gjerstad M.D., Schrader H., Gautvik K. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007, 30:969-973.
6. Peyron C., Valentin F., Bayard S., Harriot L., Bedetti C., Rousset B., et al. Melanin concentrating hormone in central hypersomnia. Sleep Med 2011, 12:768-772.
7. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. CSF hypocretin/orexin deficiency in human narcolepsy. Lancet 2000, 355:39-40.
8. Ripley B., Overeem S., Fujiki N., Nevsimalova S., Uchino M., Yesavage J., et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258.
9. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. The role of cerebrospinal fluid hypocretin measurements in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
10. Mignot E., Hayduk R., Black J., Grumet F.C., Giulleminault C. HLADQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997, 20:1012-1020.
11. Okun M.L., Lin L., Pelin Z., Hong S., Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
12. Hallmayer J., Faraco J., Lin L., Hesselson S., Winkelmann J., Kawahima M., et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009, 41:708-711.
13. Cvetkovic-Lopes V., Bayer L., Dorsaz S., Maret S., Pradervand S., Dauvilliers Y., et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy. J Clin Invest 2010, 120:713-719.
14. Han F., Lin L., Warby S.C., Faraco J., Li J., Dong S.X., et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011, 70:410-417.
15. Partinen M., Saarenpää-Heikkilä O., Ilveskoski I., Hublin C., Linna M., Olsén P., et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012, 7:e33723.
16. Heier M.S., Gautvik K.M., Wannag E., Bronder K.H., Midtlyng E., Kamaleri Y., et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1Nl influenza A. Sleep Med 2013, 14:867-871.
17. Aran A., Einen M., Lin L., Plazzi G., Nishino S., Mignot E. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. Sleep 2010, 33:1457-1464.
18. Pizza F., Franceschini C., Peltola H., Vandi S., Finotti E., Ingravallo F., et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 2013, 136(Pt. 12):3787-3795.
19. Sjögren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93years of age: establishment of reference values. Clin Chem 2001, 47:1776-1781.
20. Vanderstichele H., De Vreese K., Blennow K., Andreasen N., Sindic C., Ivanoiu A., et al. Analytical performance and clinical utility of the INNOTEST PHOSPHOTAU181P assay for discrimination between Alzheimer's disease and a dementia with Lewy bodies. Clin Chem Lab Med 2006, 44:1472-1480.
21. Paus E., Nustad K. Immunoradiometric assay for αγ- and γγ-enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles. Clin Chem 1989, 35:2034-2037.
22. Palumbo B., Siepi D., Sabalich I., Tranfaglia C., Parnetti L. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?. Funct Neurol 2008, 23:93-96.
23. Finsterer J., Exner M., Rumpold H. Cerebrospinal fluid neurone-specific enolase in mitochondrial encephalomyopathies. Metab Brain Dis 2005, 20:81-86.
24. Lee C.Y., Landreth G.E. The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010, 117:949-960.
25. Randall A.D., Witton J., Booth C., Hynes-Allen A., Brown J.T. The functional physiology of the amyloid precursor protein (APP) processing pathway. Neuropharmacology 2010, 59:243-267.
26. Weyer S.W., Klevanski M., Delekate A., Voikar V., Aidin D., Hick M., et al. APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP. EMBO J 2011, 30:2266-2280.
27. Koudinov A., Kezlya E., Koudinova N., Berezov T. Amyloid-beta, tau protein, and oxidative changes as a physiological compensatory mechanism to maintain CNS plasticity under Alzheimer's disease and other neurodegenerative conditions. J Alzheimer's Dis 2009, 18:381-400.
28. Buerger K., Ewers M., Pirtilä T., Zinkowski R., Alafuzoff I., Teipel S.J., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
29. Stenset V., Johnsen L., Kocot D., Negaard A., Skinningsrud A., Gulbrandsen P., et al. Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42. Neurology 2006, 67:830-833.
30. Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J Mol Neurosci 2011, 47:1-14.
31. Xie L., Kang H., Xu Q., Chen M.J., Liao Y., Thiyagarajan M., et al. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377.
32. Spira A.P., Gamaldo A.A., An Y., Wu M.N., Simonsick E.M., Biegel M., et al. Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol 2013, 70:1537-1543.
33. ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol 2013, 70:1544-1551.
34. Scammell T.E., Matheson J.K., Honda M., Thannickal T.G., Siegel M. Coexistence of narcolepsy and Alzheimer's disease. Neurobiol Aging 2012, 33:1318-1319.
35. Twiss J.L., Van Minnen J. New insights into neuronal regeneration: the role of axonal protein synthesis in pathfinding and axonal extension. J Neurotrauma 2006, 23:295-308.
36. Eriksson P.S. Neurogenesis and its implications for regeneration in the adult brain. J Rehab Med 2003, 41(Suppl.):17-19.
37. Curtis M.A., Erikson P.S., Faull R.L. Progenitor cells and adult neurogenesis in degenerative diseases and injuries of the basal ganglia. Clin Exp Pharmacol Physiol 2007, 34:528-532.
38. Clarkson A.N., Carmichael S.T. Cortical excitability and post stroke recovery. Biochem Soc Trans 2009, 37:1412-1414.
39. Cayre M., Canoll P., Goldman J.E. Cell migration in the normal and pathological postnatal mammalian brain. Prog Neurobiol 2009, 88:41-63.
40. Martino G., Pluchino S., Bonfanti L., Schwartz M. Brain regeneration in physiology and pathology: the immune signature driving therapeutic plasticity of normal stem cells. Physiol Rev 2011, 91:1281-1304.
41. John J., Thannickal T.C., McGregor R., Ramanathan L., Ohtsu H., Nishino S., et al. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann Neurol 2013, 74:786-793.
42. Valco P.O., Gavrilov Y.V., Yamamoto M., Reddy H., Haybaeck J., Mignot E., et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol 2013, 74:794-804.
43. Klein A.B., Jennum P., Knudsen S., Gammeltoft S., Mikkelsen J.D. Increased serum brain-derived neurotrophic factor (BDNF) levels in patients with narcolepsy. Neurosci Lett 2013, 544:31-35.
44. Gerashenko D., Murillo-Rodriguez E., Lin L., Xu M., Hallett L., Nishino S., et al. Relationship between CSF hypocretin levels and hypocretin neurone loss. Exp Neurol 2003, 184:1010-1016.
45. Levi M.S., Divine B., Hanig J.P., Doerge D.R., Vanlandingham M.M., George N.I., et al. A comparison of methylphenidate-, amphetamine-, and methamphetamine-induced hyperthermia and neurotoxicity in male Sprague-Dawley rats during the waking (lights off) cycle. Neurotoxicol Teratol 2012, 34:253-262.
46. Shiba T., Yamamoto M., Kudo W., Watanabe T., Utsumin H., Yamada K. In vivo imaging of mitochondrial function in methamphetamine treated rats. Neuroimage 2011, 57:866-872.
47. Rusyniak D.E. Neurologic manifestations of chronic methamphetamine abuse. Neurol Clin 2011, 29:641-655.
48. Silva A.P., Martins T., Baptista S., Goncalves J., Agasse E., Malva J.O. Brain injury associated with widely abused amphetamines: neuroinflammation, neurogenesis and blood-brain barrier. Curr Drug Abuse Rev 2010, 3:239-254.
49. Laske C., Stransky E., Frische A., Eschweiler G.W., Leyhe T. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Altzheimer's disease dementia. Eur Arch Psychiatry Clin Neurosci 2009, 259:80-85.
50. Kok S.W., Rolfsema F., Overeem S., Lammers G.J., Strijers R.L., Frölich M., et al. Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. J Clin Endocrinol Metab 2002, 87:5085-5091.